Calcium channel blockers: Past and future

Recent Trends on QSAR in the Pharmaeutical Perceptions

Volumn , Issue , 2012, Pages 51-62

  Duda Seiman, Corina ^a   Avram, Speranta ^b   Duda Seiman, Daniel ^c   Bumbacila, Bogdan ^c   Borcan, Florin ^c   Cinca, Rodica ^c  

^a WEST UNIVERSITY OF TIMISOARA   (Romania)

^b UNIVERSITY OF BUCHAREST   (Romania)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Angiotensin receptor blocker; Calcium channel blocker; Dihydropyridine

Indexed keywords

EID: 84882917368     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805379711201010051     Document Type: Chapter

References (42)

1. Sneader, W. Drug discovery. A history; John Wiley&Sons Ltd.: West Sussex, 2005, pp. 1- 17.
2. McDonagh, M.S.; Eden, K.B.; Peterson, K. Drug class review on calcium channel blockers. Final report; Oregon Health&Science University: Portland, 2005, pp. 5-11.
3. Tsien, R.W.; Lipscombe, D.; Madison, D.V.; Bley, K.R.; Fax, A.P. Multiple types of neuronal calcium channels and their selective modulation. Trends Neurosci., 1988, 11, 431- 438.
4. Yousef, W.M.; Omar, A.H.; Morsy, M.D.; Abd-El Wahed, M.M.; Ghanayem, N.M. The mechanism of action of calcium channel blockers in the treatment of diabetic nephropathy. Int J. Diabetes & Metabolism, 2005, 13, 76-82.
5. Clunn, G.F.; Sever, P.S.; Hughes, A.D. Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers. Int. J. Cardiol., 2010, 139(1), 2-6.
6. Berridge, M.J.; Bootman, M.D.; Roderick, H.L. Calcium signalling: dynamics, homeostasis and remodeling. Nat. Rev. Mol. Cell. Biol., 2003, 4, 517-529.
7. Talukder, M.A.H.; Zweier, J.L.; Periasamy, M. Targeting calcium transport in ischaemic heart disease. Cardiovasc. Res., 2009, 84, 345-352.
8. Shukla, N.; Rowe, D.; Hinton, J.; Angelini, G.D.; Jeremy, J.Y. Calcium and the replication of human vascular smooth muscle cells: studies on the activation and translocation of extracellular signal regulated kinase (ERK) and cyclin D1 expression. Eur. J. Pharmacol., 2005, 509, 21-30.
9. Cristofori, P.; Crivellente, F.; Campagnola, M. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice treated with lacidipine is associated with a decreased susceptibility of low-density lipoprotein to oxidation. Int. J. Exp. Pathol., 2004, 85, 105- 114.
10. Godfraind, T. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Phil. Trans R. Soc. B., 2005, 360, 2259-2272.
11. Morimoto, Y.; Kureishi-Bando, Y.; Murohara, T. Calcium antagonists: current and future applications based on new evidence. Pleiotropic effects of calcium channel blockers on vascular endothelial function. Clin. Calcium, 2010, 20, 69-75.
12. Nishiyama, A.; Nakano, D.; Hitomi, H. Calcium antagonists: current and future applications based on new evidence. Effects of calcium channel blockers on oxidative stress. Clin. Calcium, 2010, 20, 38-44.
13. Matsumori, A.; Nishio, R.;Nose, Y. Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells. Circ. J., 2010, 74, 567-571.
14. Eickelberg, O.; Roth, M.; Mussmann, R. Calcium channel blockers activate the interleukin- 6 gene via the transcription factors NF-IL6 and NF-kappaB in primary human vascular smooth muscle cells. Circulation, 1999, 99, 2276-2282.
15. Hataji, K.; Watanabe, T.; Oowada, S. Effects of a calcium-channel blocker (CV159) on hepatic ischemia/reperfusion injury in rats: evaluation with selective NO/pO2 electrodes and an electron paramagnetic resonance spin-trapping method. Biol. Pharm. Bull., 2010, 33, 77-83.
16. Staessen, J.A.; Wang, J.G.; Thijs, L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet., 2001, 358, 1305-1315.
17. Rothwell, P.M.; Howard, S.C.; Dolan, E. Sever PS on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of ß blockers and calcium-channel blockers on withinvariability in blood pressure and risk of stroke. The Lancet Neurology, 2010, 9, 469-480.
18. Anonymous. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288, 2981-2997.
19. Neoptolemos, J.P.; Kemppainen, E.A.; Mayer, J.M. Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study. Lancet., 2000, 355, 1955-1960.
20. Opie, L.H.; Phil, D.; Schall, R. Evidence-based evaluation of calciumchannel blockers for hypertension. J. Am. Coll. Cardiol., 2002, 39, 315-322.
21. Jamerson, K.; Weber, M.A.; Bakris, G.L. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med., 2008, 359, 2417-2428.
22. Trenkwalder, P. Antihypertensive treatment with calcium channel blockers: pharmacological pornography or useful intervention? Nephrol. Dial. Transplant, 2004, 19, 17-20.
23. Pahor, M.; Psaty, B.M.; Alderman, M.H. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet., 2000, 356, 1949-1954.
24. Staessen, J.A.; Li, Y.; Thijs, L.; Wang, J.G. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res., 2005, 28, 385-407.
25. Nissen, S.E.; Tuzcu, E.M.; Libby, P. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA, 2004, 292, 2217-2226.
26. Julius, S.; Kjeldsen, S.E.; Weber, M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet, 2004, 363, 2022-2031.
27. Destro, M.; Luckow, A.; Samson, M.; Kandra, A.; Brunel, P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J. Am. Soc. Hypertens, 2008, 2, 294-302.
28. Schrader, J.; Salvetti, A.; Calvo, C. The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int. J. Clin Pract., 2009, 63, 217-225.
29. Elijovic, F.; Laffer, C. A role of single-pill triple therapy in hypertension. Ther. Adv. Cardiovasc Dis. 2009, 3, 231-240.
30. Frampton, J.E.; Scott, L.J. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. Am. J. Cardiovasc Drugs, 2009, 9, 309-330.
31. Wang, J.G. A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention. Vascular Health and Risk Management, 2009, 5, 593-605.
32. Messerli, F.H.; Noll, G.; Lindholm, L.H.; Haller, H.; Ruilope, L.M.; Volpe, M. The role of dihydropyridine calcium channel blockers in the treatment of hypertension and cardiovascular disease - an update. Eur. Cardiovasc. Dis., 2006, 1, 1-6.
33. Chapman, R.H.; Yeaw, J.; Roberts, C.S. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovascular Disorders, 2010, 10, 29.
34. Li, X.; Li, J.; Nguyen, T. Effect of statins and calcium channel blockers on all-cause mortality and cardiovascular and cerebrovascular disease mortality in 958 chinese hospitalized patients with peripheral arterial disease after 13 months of follow-up. Journal of Health Science, 2007, 53, 226-233.
35. Kondo, T.; Goto, R.; Sonoda, K. Plasma rennin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients. Intern. Med., 2010, 49, 637-643.
36. Nakamura, E.; Akashi, H.; Hiromatsu, S.; Tanaka, A.; Onitsuka, S.; Aoyagi, S. Azelnidipine dicreases plasma matrix metalloproteinase-9 levels after endovascular abdominal aortic aneurysm repair. Kurume Medical Journal, 2009, 56, 25-32.
37. Takahara, A. Cilnidipine: a new generation Ca2+ channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovascular Therapeutics, 2009, 27, 124-139.
38. Li, Y.; Cao, Z. Cardiovascular drugs. In: Clinical toxicology. Principles and mechanisms. Barile, F.A., Ed.; CRC Press LLC: Boca Raton, 2004; pp. 207-222.
39. Kubinyi, H. 3D-QSAR in drug design: theory, methods and applications; ESCOM Science: Leiden, 1993, pp. 12-18.
40. Gupta, S.P. QSAR studies on calcium channel blockers. Top Heterocycl. Chem., 2006, 4, 251-289.
41. Schleifer, K.J. Comparative molecular modelling study of the calcium channel blockers nifedipine and black mamba toxin FS2. J. Comput-Aided Mol Des., 1997, 11, 491-501.
42. Gupta, S.P.; Veerman, A.; Bagaria, P. Quantitative structure-activity relationship studies on some series of calcium channel blockers. Molecular Diversity. 2004, 8, 357-363.